Agilis’s AGIL-FA Gets Orphan Drug Designation

The FDA has granted orphan drug designation for Agilis’s gene therapy candidate AGIL-FA.

The product is being developed to treat the degenerative neuromuscular disorder Friedreich’s ataxia.

Agilis says it is the first company to receive orphan drug designation from the FDA for a gene therapy to treat the condition.